A Study of NST-6179 in Adult Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

Key Inclusion Criteria:

   - Adult persons aged 18 years or older at the time of informed consent.

   - Minimum of 6 months on Parenteral supplementation.

   - Established clinical diagnosis of IFALD based on a persistent elevation of

      1. liver enzymes (ALP, AST, ALT, or GGT ≥1.5 × upper limit of normal [ULN]) for ≥6
      months and/or

      2. total bilirubin > ULN for ≥6 months.

   - Laboratory parameters consistent with stable liver disease without cirrhosis as
   defined by:

      1. ALT and AST <5 × ULN;

      2. Total bilirubin ≤2.0 mg/dL in the absence of Gilbert's Syndrome.

      3. Serum albumin ≥3 g/dL;

      4. International normalized ratio (INR) ≤1.3 in the absence of anticoagulant
      therapy;

      5. Platelet count ≥120,000/mm3.

Key Exclusion Criteria:

   - Clinical, laboratory, imaging, or histopathologic evidence of other causes of acute or
   chronic liver disease, including autoimmune, viral, metabolic, or alcoholic liver
   disease.

   - Clinical evidence of compensated or decompensated hepatic cirrhosis as assessed by
   historical liver histology, ultrasound-based and/or signs and symptoms of hepatic
   decompensation (including, but not limited to, jaundice, ascites, variceal hemorrhage,
   and/or hepatic encephalopathy).

   - Presence of hepatic impairment, end-stage liver disease, and/or a model for end-stage
   liver disease (MELD) score >12.

   - Transient elastography read >20.0 kPA within 3 months prior to or during the Screening
   Period.

   - Estimated glomerular filtration rate <45 mL/min based on the 2021 CKD-EPI creatinine
   equation.

   - Poor nutritional status defined as body mass index (BMI) <17 kg/m2.